LCM

Lynx1 Capital Management Portfolio holdings

AUM $346M
1-Year Est. Return 2.97%
This Quarter Est. Return
1 Year Est. Return
-2.97%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$279M
AUM Growth
+$12.5M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
20
New
Increased
Reduced
Closed

Top Buys

1
+$35.4M
2
+$17.5M
3
+$14.8M
4
STOK icon
Stoke Therapeutics
STOK
+$697K
5
CCCC icon
C4 Therapeutics
CCCC
+$393K

Top Sells

1
+$8.61M
2
+$4.39M
3
+$1.08M
4
VOR icon
Vor Biopharma
VOR
+$707K
5
MRUS icon
Merus
MRUS
+$505K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$837M
$71.1M 25.45%
6,443,940
+1,584,946
MRUS icon
2
Merus
MRUS
$7.22B
$66M 23.65%
1,568,841
-12,000
PTGX icon
3
Protagonist Therapeutics
PTGX
$4.95B
$35.4M 12.69%
+733,014
STOK icon
4
Stoke Therapeutics
STOK
$1.31B
$35.2M 12.6%
5,291,929
+104,738
CGEM icon
5
Cullinan Oncology
CGEM
$425M
$24.3M 8.72%
3,215,722
+1,957,927
ALLO icon
6
Allogene Therapeutics
ALLO
$262M
$16.1M 5.78%
11,057,009
+182,286
CCCC icon
7
C4 Therapeutics
CCCC
$218M
$11.4M 4.07%
7,098,133
+245,389
TCRX icon
8
TScan Therapeutics
TCRX
$61.9M
$7.39M 2.65%
5,357,347
DTIL icon
9
Precision BioSciences
DTIL
$81.4M
$3.65M 1.31%
766,051
IBIO icon
10
iBio
IBIO
$26.7M
$3.47M 1.24%
862,279
PASG icon
11
Passage Bio
PASG
$20M
$3.27M 1.17%
462,848
UPB
12
Upstream Bio Inc
UPB
$1.24B
$1.34M 0.48%
219,247
-20,795
NEUP
13
Neuphoria Therapeutics
NEUP
$9.67M
$264K 0.09%
45,806
DSGN icon
14
Design Therapeutics
DSGN
$431M
$255K 0.09%
+65,954
ALLK
15
DELISTED
Allakos
ALLK
– –
-3,628,144
CNTA
16
Centessa Pharmaceuticals
CNTA
$2.97B
– –
-17,400
CRBU icon
17
Caribou Biosciences
CRBU
$195M
– –
-680,189
KROS icon
18
Keros Therapeutics
KROS
$494M
– –
-544,001
RPTX icon
19
Repare Therapeutics
RPTX
$72.6M
– –
-79,176
VOR icon
20
Vor Biopharma
VOR
$128M
– –
-637,218